Extended Release Formulations of Oxybutynin and Tolterodine for the Treatment of Overactive Bladder: A German Health Economic Analysis
El-Hadi W1, Getsios D1, Caro J J1, Duchesne I2, Feng W2, Dubois D2 1. Caro Research Institute, 2. Johnson & Johnson Pharmaceutical Services LLC
Abstract Category
Epidemiology & Outcomes Research
| Abstract 409 |
| Read By Title:
Scientific Non Discussion Abstract Session 21 |
|